tbuckley/cabot-search huggingface dataset:
Optimizing Training Response for Women in Cardiac Rehabilitation
Authors: Sherrie Khadanga, Patrick D. Savage, Anton Pecha, Jason Rengo, Philip A. Ades
Journal: JAMA Cardiology (2021)

Despite lower baseline fitness levels, women in cardiac rehabilitation (CR) do not typically improve peak aerobic exercise capacity (defined as peak oxygen uptake [peak Vo2]) compared with men in CR.To evaluate the effect of high-intensity interval training (HIIT) and intensive lower extremity resistance training (RT) compared with standard moderate intensity continuous training (MCT) on peak Vo2 among women in CR.This randomized clinical trial conducted from July 2017 to February 2020 included women from a community-based cardiac rehabilitation program affiliated with a university hospital in Vermont. A total of 56 women (mean [SD] age, 65 [11] years; range 43-98 years) participating in CR enrolled in the study.MCT (70% to 85% of peak heart rate [HR]) with moderate intensive RT or HIIT (90% to 95% of peak HR) along with higher-intensity lower extremity RT 3 times per week over 12 weeks.The primary outcome was the between-group difference in change in peak Vo2 (L/min) from baseline to 12 weeks.Peak Vo2 increased to a greater degree in the HIIT group (+23%) than in the control group (+7%) (mean [SD] increase, 0.3 [0.2] L/min vs 0.1 [0.2] L/min; P = .03). Similarly, the change in leg strength was greater in the HIIT-RT group compared with the control group (mean [SD] increase, 15.3 [0.3] kg vs 6.4 [1.1] kg; P = .004).An exercise protocol combining HIIT and intensive lower extremity RT enhanced exercise training response for women in CR compared with standard CR exercise training. Women randomized to HIIT experienced significantly greater improvements in both peak Vo2 and leg strength during CR.ClinicalTrials.gov Identifier: NCT03438968.
Abstract 11436: Trends in Consumer Wearable Devices in a Primary Care Cohort
Authors: Mostafa A Al-alusi, Shaan Khurshid, Xin Wang, Christopher Reeder, Pulkit Singh, Rachael Venn, Daniel Pipilas, Anthony A Philippakis, Jeffrey M Ashburner, Patrick T Ellinor, Daniel E Singer, Steven J Atlas, Andrea Foulkes, Jennifer E Ho, Christopher D Anderson, Puneet Batra, Steven A Lubitz
Journal: Circulation (2021)

Introduction: Consumer wearable devices that record data relevant to cardiac health are widely available. However, whether providers find these devices relevant to clinical care, and in which patients, is unknown. Methods: We identified mention of wearable devices in provider notes between 2005 and 2020 in an EHR cohort of primary care patients in the Mass General Brigham healthcare system. Outpatient notes containing &gt;250 characters were included. Search terms included “AliveCor,” “Apple Watch,” “Fitbit,” “Garmin,” “smartwatch,” “fitness tracker,” and alternative spellings. Demographics and cardiovascular comorbidities were compared between patients with and without device mentions. Notes with and without device mention were compared with respect to clinic type and diagnosis codes occurring on the same date. Incidence rates for device mention were calculated for each year. Results: The final sample comprised 494,254 patients and 27,221,019 notes. The mean age was 49.1 ± 17.0 years, and median follow-up was 6.9 (Q1 2.7, Q3 11.9) years. A total of 8,955 (1.8%) patients had ≥1 note mentioning a device. The proportion of notes mentioning devices increased over time (Figure), with increased incidence of device mention from 0.006 to 7.5 per 1000 person-years between 2005 and 2019. Most patients with device mentions were female (69.4%) and white (86.7%). At the time of first device mention, the mean age was 55.3 ± 14.0 years and 1,183 (13.2%) patients had prevalent atrial fibrillation (AF). Cardiology clinic notes comprised a greater proportion of notes with device mentions versus notes without device mentions (15.7% [5,336] vs 3.7% [996,971], p&lt;0.001). A total of 9.3% (3,160) of notes with device mentions had same-day diagnosis codes for AF, versus 2.7% (730,614) of notes without device mentions (p &lt; 0.001). Conclusion: Provider mention of consumer wearable devices in EHR notes has increased over time, and is associated with cardiology clinic notes and diagnosis codes for AF.
CTNI-43. CXCL12 INHIBITION IN MGMT UNMETHYLATED GLIOBLASTOMA – RESULTS OF AN EARLY PROOF-OF-CONCEPT ASSESSMENT IN THE MULTICENTRIC PHASE I/II GLORIA TRIAL (NCT04121455)
Authors: Frank Giordano, Julian Layer, Sonia Leonardelli, Lea Friker, Clemens Seidel, Thomas Zeyen, Christina Schaub, Elena Sperk, Katharina Sahm, Sied Kebir, Peter Hambsch, Torsten Pietsch, Martin Glas, Sotirios Bisdas, Michael Hölzel, Ulrich Herrlinger
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Preclinical studies showed that CXCL12-mediated influx of highly angiogenic monocytes/macrophages is a key driver of tumor re-vascularization and re-growth after radiotherapy (RT) of glioblastoma (GBM). We report findings from a phase I/II proof-of concept (PoC) study on CXCL12 inhibition during and after RT of GBM. METHODS Patients ≥18years with incompletely or unresected GBM without MGMT promoter hypermethylation and ECOG≤2 were eligible to participate. Patients received continuous (24/7) i.v. infusions of 200mg/week (n=3), 400mg/week (n=3) or 600mg/week (n=3) of the CXCL12 inhibitor olaptesed pegol (OLA) for 26 weeks during and after normo- or hypofractionated RT (60Gy/40.05Gy). The primary endpoint was safety as per the incidence of treatment-related adverse events. The study was accompanied by PoC-research including multiparametric MRI biomarkers (relative cerebral blood volume, rCBV; fractional tumor burden with high perfusion, FTBhigh; apparent diffusion coefficient, ADC) and of multiplexed immunofluorescence imaging (CODEX®) of reference and patient samples. Initial results of these analyses are reported for the first six patients enrolled. RESULTS Five of six (83%) patients assessed with advanced MRI showed response under OLA in rCBV/FTBhigh and ADC. Maximum reduction in perfusion (rCBV) from baseline was 55%, maximum reduction of FTBhigh was 55% and maximum increase in ADC was 77%. Furthermore, five of six (83%) patients analyzed showed reduction of enhancing tissue volumes in at least one scan under OLA therapy. In both one patient and two reference samples CXCL12 co-localized with endothelial cells of the microvascular proliferation zone. In a paired sample (before/during OLA) of one patient, endothelial cells stained positive for CXCL12 before but not during treatment and almost all GBM cells were negative in Ki67 staining in the sample obtained under OLA therapy. CONCLUSIONS Advanced MRI and multiplexed immunofluorescence suggest efficacy of combined radiotherapy and CXCL12 inhibition in unmethylated GBM. Funded by NOXXON Pharma AG; ClinicalTrials.gov number, NCT04121455.
Managing doctors and health care
Authors: R. Moore
Journal: BMJ (2000)

The sexual health of boys and men Commercial advertisements are needed to create a condom cultureEditor-Yamey highlighted the need for work on the sexual health of boys and men, and he identified education and service provision as the key factors in increasing condom use, among other outcomes. 1Both of these factors fail to address the underlying problem, that condoms are unpopularthey are far short of desired items among young men in particular.A major factor influencing cultural attitudes is not education or services but the media.Global marketing, vast advertising budgets, and sexual imagery are used to sell items as diverse as chocolate bars and sanitary products on television.However, noticeably absent in the United Kingdom is any commercial television advertisement promoting particular condom brands or targeted to the growing market for condoms.Consequently, the promotion of condom use falls largely on public sector bodies.Education and health bodies have already made condoms more available to young people and developed an understanding of their health benefits.However, without a cultural move making condom use popular, such efforts have limited success as health promotion fights to convince people to use unpopular products.Partly as a result, sexually transmitted infections in young people are increasing in England, 2 and there are 90 000 teenage conceptions a year. 3ondoms are produced commercially and lend themselves to many images that are used to market other products successfully, so you would predict a deluge of television adverts promoting one brand above another.Antiquated advertising rules may explain why this has not happened.Those governing condom advertisements on UK television expressly forbid companies from showing the product unwrapped, and consequently the image of an unwrapped condom cannot be normalised or promoted. 4Advertising limitations also dictate social responsibility in advertisements and prohibit anything promoting promiscuity.How far these other measures limit advertisers seems to be unknown, but such restrictions should be measured against the numerous television hours showing promiscuity without any reference to condoms.Furthermore, these considerable restrictions on condom advertising may prevent movement of new producers into markets and consequently stifle the competition necessary to refine marketing and product development.The government is pursuing strategies in communicable disease, sexual health, and HIV, as well as reductions in teenage pregnancy. 3Pragmatic revisions to existing rules on the commercial advertising of condoms may allow commercial interests to work with those of health to alter the image of condoms and increase markets (particularly among young people) in order to help reduce sexually transmitted infections and unwanted pregnancies.
Retraction Notice to: miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells
Authors: Jing Xiao, Yankun Liu, Fuxia Wu, Ruiyan Liu, Yongli Xie, Qian Yang, Yufeng Li, Min Liu, Shengping Li, Hua Tang
Journal: Molecular Therapy (2021)

Main text(Molecular Therapy 28, 587–598; February 2020)Molecular Therapy is retracting this article. We investigated concerns of image duplication raised by a reader, identifying 10 instances of duplication of the same image panel for different experiments in Figures 3, 5, and 6. This re-use of data without appropriate attribution represents a severe abuse of the scientific publishing system. Given these issues, we are retracting the paper. Main text(Molecular Therapy 28, 587–598; February 2020)Molecular Therapy is retracting this article. We investigated concerns of image duplication raised by a reader, identifying 10 instances of duplication of the same image panel for different experiments in Figures 3, 5, and 6. This re-use of data without appropriate attribution represents a severe abuse of the scientific publishing system. Given these issues, we are retracting the paper. (Molecular Therapy 28, 587–598; February 2020) Molecular Therapy is retracting this article. We investigated concerns of image duplication raised by a reader, identifying 10 instances of duplication of the same image panel for different experiments in Figures 3, 5, and 6. This re-use of data without appropriate attribution represents a severe abuse of the scientific publishing system. Given these issues, we are retracting the paper. RETRACTED: miR-639 Expression Is Silenced by DNMT3A- Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer CellsXiao et al.Molecular TherapyNovember 28, 2019In BriefThis article has been retracted: please see Elsevier Policy on Article Withdrawal ( https://www.elsevier.com/about/our-business/policies/article-withdrawal ). This article has been retracted at the request of the editors.Molecular Therapy is retracting this article. We investigated concerns of image duplication raised by a reader, identifying 10 instances of duplication of the same image panel for different experiments in Figures 3, 5, and 6. This re-use of data without appropriate attribution represents a severe abuse of the scientific publishing system. Full-Text PDF Open Archive
Abstract 10470: Comparison Between the Double-Syringe Technique and the Single-Syringe Diluted with Normal Saline Technique of Adenosine for a Termination of Supraventricular Tachycardia: A Pilot, Randomized, Single-Blind Controlled Trial (Do-Single Trial)
Authors: Praew Kotruchin, Itchaya-on Chaiyakhan, Phimonphorn Kamonsri, Wittawin Chantapoh, Nattapat Serewiwattana, Nayawadee Kaweenattayanon, Thapanawong Mitsungnern
Journal: Circulation (2021)

Introduction: Supraventricular tachycardia (SVT) is a condition commonly found in emergency settings. Adenosine is recommended as the first-line treatment for stable patients, however, it is rapidly metabolized. The ACLS guidelines recommend administration of 6-mg adenosine intravenously (IV) with an immediate 20-ml normal saline solution (NSS) IV (double syringe technique; DST). However, adenosine diluted with NSS up to 20 ml IV (single syringe technique; SST) was as well found effective for terminating the arrhythmia. Hypothesis: The SST is non-inferior to the DST for terminating stable SVT. Methods: A pilot, single-blind, randomized, controlled study was conducted from January to December 2020 at 4 hospitals in the northeastern region, Thailand. Thirty patients who presented with stable regular narrow complex tachycardia, diagnosed as stable SVT by cardiologists, were enrolled. They were randomized into the DST and SST groups, 15 patients each. We evaluated the termination of SVT (turned to normal sinus rhythm), the average successful doses, and the complication rate of each group. Analyses were based on the intention to treat principle. Results: The termination rate was 91.7% and 83.3% in the DST and the SST group, P =0.990. The success rate of 6-mg adenosine was 75% and 66.7% in the DST and the SST group, P =0.640. The total administration dose was 8.2±4.9 mg in the DST group, and 10.0±5.9 mg in the SST group, P =0.432. There was no difference in the complication rate between both groups. Conclusions: Adenosine diluted with NSS up to 20 ml administered IV was non-inferior to the conventional technique for terminating SVT. A further definitive study with larger sample size is required.
Abstract 11814: Definitive Diagnostic Yield in a Referral Population is Similar to That of Cascade Genetic Screening
Authors: Zahra Aryan, Julia Nascimben, Calum A Macrae
Journal: Circulation (2021)

Introduction: We aimed to investigate the prevalence of a definitive diagnosis among those who were referred for assessment of a suspected inherited cardiovascular disorders (CVD) compared to cascade screening. Methods: A retrospective cohort study was conducted in an adult cardiovascular genetics referral center from 2015 to 2021. Data on initial manifestations, family history, laboratory results, ECG, echocardiogram, cardiac MRI, genetic testing, treatment, and clinical outcome was extracted. Participants were categorized as; 1) definitively diagnosed; individuals who met the diagnostic criteria of a specific inherited CVD 2) overlap diagnosis: individuals with abnormal phenotypes or a positive definitive genetic finding who failed to meet the diagnostic criteria of a certain inherited CVD, and 3) normal: individuals in whom there was no objective evidence of an inherited CVD. The yield of definitive diagnosis for those who were referred for assessment of a suspected inherited CVD (referred group) was compared with proband-initiated cascade screening. Results: A total of 503 patients (51.5% female, mean age of 43 years) with 1153 person-years follow up were studied. Of these individuals, 174 (34.6%) were seen for cascade screening. After comprehensive evaluation a definitive diagnosis of an inherited CVD was made in 202 (40.1%), 187 (37.2%) were effectively normal and 114 (22.6%) were in the overlap diagnosis category. There was no significant difference in the yield of definitive diagnosis in the referred group when compared to those assessed during cascade screening (39.7% vs. 40.4%, p=0.86). Conclusions: The proportions of definitive diagnoses and overlap diagnoses are similar in comprehensive CVD genetic evaluations whether referred on the basis of physician suspicion or screened due to relatedness to definitive probands. These data suggest that current inherited CVD syndrome definitions are incomplete and may lead to errant misclassification.
QOLP-07. EXPLORING CALM IN PATIENTS WITH HIGH-GRADE GLIOMA
Authors: Ashlee Loughan, Kelcie Willis, Autumn Lanoye, Sarah Braun, Gary Rodin, Alexandria Davies, Dace Svikis, Suzanne Mazzeo, Leroy Thacker, Mark Malkin
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Patients with high-grade glioma report substantial psychological distress, yet are frequently excluded from psycho-oncology research. Managing Cancer and Living Meaningfully (CALM) is an expressive-supportive psychotherapy designed to address the inevitable challenges that patients with advanced cancer face. CALM was shown in a large randomized controlled trial to reduce depression and death-related distress, but brain cancer was an exclusion criterion. METHODS In this ongoing ORBIT Model Phase Ib Refine trial, 10 adults with high-grade glioma and heightened distress (PHQ/DADDS) participated in CALM. Feasibility and acceptability were assessed based on established metrics, satisfaction was explored by surveys and exit-interviews, and preliminary efficacy of reducing distress was analyzed by pre to post-CALM paired t-tests; effect sizes estimated using Cohen’s d. RESULTS Of 11 patients referred and screened, 10 enrolled in the study (91% enrollment rate; 70% GBM; 70% female; M age =55yrs). Reasons for withdrawal was disinterest in intervention topics (n=2). Eight patients completed baseline assessments and at least one CALM session. To date, seven have completed treatment. Retention is 63%, with one participant still in active treatment. No adverse events were determined to be study-related. Perceived benefit was high (4.8/5), and all participants reported they would recommend program to others. Pre- to post-CALM analyses show medium-to-large effects on reducing depression (d=1.2), anxiety (d=.74), and death-related distress (d=.54). Small effects were seen for quality-of-life improvement (d=.26). Fear of cancer recurrence worsened (d=.75). CONCLUSIONS Preliminary data suggests that CALM is both feasible and acceptable in adult patients with high-grade glioma. Enrollment and retention rates were adequate. Patients reported high benefit and recommendation to others. Depression, generalized anxiety, and death-related distress all improved with medium-to-large effects, suggesting CALM may be a promising intervention for high-grade glioma patients as they navigate the challenges of brain cancer. Adjunctive treatment may be necessary to address fear of cancer recurrence.
Alleviating Oxidative Injury of Myocardial Infarction by a Fibrous Polyurethane Patch with Condensed ROS‐Scavenging Backbone Units
Authors: Jieqi Xie, Yuejun Yao, Shuqin Wang, Linge Fan, Jie Ding, Yun Gao, Shifen Li, Liyin Shen, Yang Zhu, Changyou Gao
Journal: Advanced Healthcare Materials (2021)

Abstract Excessive reactive oxygen species (ROS) generated after myocardial infarction (MI) result in the oxidative injury in myocardium. Implantation of antioxidant biomaterials, without the use of any type of drugs, is very appealing for clinical translation, leading to the great demand of novel biomaterials with high efficiency of ROS elimination. In this study, a segmented polyurethane (PFTU) with a high density of ROS‐scavenging backbone units is synthesized by the reaction of poly(thioketal) dithiol (PTK) and poly(propylene fumarate) diol (PPF) (soft segments), thioketal diamine (chain extender), and 1,6‐hexamethylene diisocyanate (HDI). Its chemical structure is verified by gel permeation chromatography (GPC), 1 H nuclear magnetic resonance ( 1 H NMR) spectroscopy, and Fourier transform infrared (FTIR) spectroscopy. The electrospun composite PFTU/gelatin (PFTU/Gt) fibrous patches show good antioxidation capacity and ROS‐responsive degradation in vitro. Implantation of the PFTU/gelatin patches on the heart tissue surface in MI rats consistently decreases the ROS level, membrane peroxidation, and cell apoptosis at the earlier stage, which are not observed in the non‐ROS‐responsive polyurethane patch. Inflammation and fibrosis are also reduced in the PFTU/gelatin‐treated hearts, resulting in the reduced left ventricular remodeling and better cardiac functions postimplantation for 28 d.
Emerging landscape of cell-penetrating peptide-mediated nucleic acid delivery and their utility in imaging, gene-editing, and RNA-sequencing
Authors: Jingping Geng, Xuan Xia, Lin Teng, Lidan Wang, Linlin Chen, Xiangli Guo, Bonn Belingon, Jason Li, Xuemei Feng, Xianghui Li, Wendou Shang, Yingying Wan, Hu Wang
Journal: Journal of Controlled Release (2021)
NIMG-62. 68(GA)DOTATATE PET-BASED RADIATION CONTOURING CREATES SMALLER AND MORE PRECISE RADIATION VOLUMES FOR MENINGIOMA PATIENTS
Authors: Haley Perlow, Michael Yang, Michael Siedow, Yevgeniya Gokun, Joseph McElroy, Jennifer Matsui, Sasha Beyer, Andrea Arnett, Daniel Boulter, Joel Fritz, Eric Miller, Dukagjin Blakaj, Wesley Zoller, Catherine Cadieux, Daniel Eiler, Mark Addington, Dominic DiConstanzo, John Grecula, Raju Raval, Arnab Chakravarti, Joshua Palmer
Journal: Neuro-Oncology (2021)

Abstract PURPOSE Radiation treatment planning for meningiomas conventionally involves MRI contrast enhanced images to define residual tumor. However, the gross tumor volume may be difficult to delineate for patients with a meningioma in the skull base, sagittal sinus, or post resection. Advanced PET imaging using 68(GA)DOTATATE PET, which has been shown to be more sensitive and specific than MRI imaging, can be used for target volume delineation in these circumstances. We hypothesize that 68(GA)DOTATATE PET scan-based treatment planning will lead to smaller radiation volumes and will detect additional areas of disease compared to standard MRI alone. METHODS Our data evaluated retrospective, deidentified, and blinded gross tumor volume (GTV) contour delineation with 7 CNS specialists (3 neuroradiologists, 4 CNS radiation oncologists) for 26 patients diagnosed with a meningioma who received both a 68(GA)DOTATATE PET and an MRI for radiation treatment planning. Both the MRI and the PET were non-sequentially contoured by each physician for each patient. RESULTS The mean MRI volume for each physician ranged from 24.14-35.52 ccs. The mean PET volume for each physician ranged from 10.59-20.54 ccs. The PET volumes were significantly smaller for 6 out of the 7 physicians. In addition, 7/26 (27%) patients had new non-adjacent areas contoured on PET by at least 6 of the 7 physicians that were not contoured by these physicians on the corresponding MRI. These new areas would not have been in the traditional MRI based volumes. CONCLUSION Our study supports that 68(GA)DOTATATE PET imaging can help radiation oncologist create smaller and more precise radiation treatment volumes. Utilization of 68(GA)DOTATATE PET may find undetected areas of disease which in turn can improve local control and progression free survival. 68(GA)DOTATATE PET guided treatment planning should be studied prospectively.